Global and Targeted Proteomic Strategies for Biomarker Discovery: Technology Comparison and Assay Development for the Identification of Putative Ovarian Cancer Biomarkers
Year: 2011
Type: dissertation
Abstract: A molecular biomarker is a measurable indicator for biological or pathogenic processes, e.g. a metabolite, DNA methylation or a protein. The promise of clinical proteomics is to discover and validate such protein biomarkers by virtue of MS-based technologies. Recently, communal efforts are undertaken to streamline this process by application of new technological platforms in a strategic manner. A so-called “MS-based biomarker discovery pipeline” has been proposed, in which putative biomarkers are first discovered from clinically relevant patients’ samples in global proteomics experiments. Subsequently, promising candidates are verified in a multiplexed fashion using targeted quantification methods (i.e. selected reaction monitoring-MS; SRM-MS) in independent sample sets. The few candidates successful in this initial verification might then proceed to more thorough validation by well-established methods (e.g. ELISA) in large patient cohorts. The aim of this thesis was two-fold: First, experiments with different sample types were designed to deliver the first direct comparison between two state-of-the-art proteomics platforms, thus further evaluating their capabilities for use in clinical proteomics. Samples originating from a highly complex HEK whole cell lysate, a membrane-enriched fraction from murine C2C12 skeletal muscle cells, and a proximal tissue fluid (ascitic fluid) were subjected to replicate analysis by OFFGEL (12 fractions, pH 3 – 10) followed by RP-LC-MS/MS or 12-step on-line Multidimensional Protein Identification Technology (MudPIT) to allow for a comprehensive performance evaluation. These experiments showed that OFFGEL achieves superior peptide focussing as compared to MudPIT: Depending on the sample, 76 – 88 % of peptides were binned into one fraction, whereas with MudPIT, only 36 – 61 % of peptides were detected in only one step of the analysis. However, both platforms performed equally in regards to the numbers of identified peptides and proteins for the membrane-enriched C2C12 samples (1428 proteins identified with MudPIT, 1398 with OFFGEL-LC-MS/MS) and ascitic fluid samples (346 proteins identified with MudPIT, 461 with OFFGEL-LC-MS/MS). Interestingly, for the highly complex HEK samples, better peptide focussing by OFFGEL-LC-MS/MS apparently resulted in a higher number of identified proteins (3143 vs. 2242 with MudPIT). Experiments with the membrane-enriched C2C12 samples demonstrated equal performance of both techniques for the analysis of highly hydrophobic transmembrane proteins. In summary, it was concluded that the choice of method is dependent on the requirements of the project: The highly automated MudPIT might be advisable for routine proteome analyses, possibly in limited sample volumes. The more cost- and labour-intensive OFFGEL fractionation, on the other hand, might be a valuable alternative for studies demanding a high degree of peptide separation. The second aim of the thesis was a proof-of-concept application of a MS-based biomarker discovery pipeline to identify putative biomarker proteins for serous ovarian cancer, a malignancy for which reliable biomarkers are scarce. Ascitic fluid samples from patients with serous-type epithelial ovarian cancer were analyzed using both OFFGEL-LC-MS/MS and MudPIT. These experiments yielded a comprehensive description of the ascitic fluid proteome with more than 500 protein identifications, which can serve as a valuable resource for future ovarian cancer research. Additionally, a semi-quantitative comparison using MudPIT and assessing relative protein abundances by Spectral Counting between ascitic fluid samples from ovarian cancer patients and from women with benign tumours of the ovary revealed 43 proteins, which were of higher abundance in the cancerous sample group. Integration of this data with published transcriptomic and proteomic datasets led to a panel of 51 biomarker candidate proteins. Systematic SRM-MS assay development was performed for a subset of thirteen of these candidates using synthetic peptides. Preliminary SRM-MS measurements in ascitic fluid samples guided the selection of four candidates for precise quantification by stable isotope dilution-SRM-MS (SID-SRM-MS) in independent ascitic fluid (n=10) and serum samples (n=20). These experiments showed small (~2x) but significant elevations of the concentration of the three candidate proteins MSLN, GAPDH, and PKM1/2 in both ascitic fluid and serum samples of cancer patients as compared to control groups. The results demonstrate that the applied pipeline workflow can serve as a template for the proteomics-based discovery of cancer biomarkers and deliver further evidence for the implication of short-listed biomarker candidates in ovarian cancer biology.
Author: Elschenbroich, Sarah
Institution: Friedrich-Alexander-Universität Erlangen-Nürnberg
Language: German
Subfield: Spectroscopy
Field: Chemistry
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W7000605737
